High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study
Jia Ruan(Cornell University), Leandro Cerchietti(Cornell University), Grigorii Nos(Addgene), Vladislav Maksimov(Addgene), Ari Melnick(Cornell University), Michael Sigouros(Cornell University), Riyaad Rahim(NewYork–Presbyterian Hospital), Lubomir Sokol(Moffitt Cancer Center), John P. Leonard(New York University), Peter Martin(Northwestern University), Koen van Besien(University Hospitals of Cleveland), Andrea Sboner(Cornell University), Olivier Elemento(Cornell University), Alison J. Moskowitz, Neha Mehta–Shah(The University of Texas MD Anderson Cancer Center), Steven M. Horwitz(Memorial Sloan Kettering Cancer Center), María V. Revuelta(Cornell University), Morton Coleman(Cornell University), Sarah C. Rutherford(NewYork–Presbyterian Hospital), Nikita Kotlov(Addgene), Zhengming Chen(Cornell University), Erin Mulvey(Cornell University), Wei Song(University of Alabama at Birmingham), Giorgio Inghirami(Cornell University)
Cited by 11
Related Papers
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k